Alkem Laboratories reported below the market expectation for Q4FY21 By Mr. Yash Gupta, Angel Broking Ltd
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Below are Quote on Alkem Laboratories reported below the market expectation for Q4FY21 by Mr. Yash Gupta Equity Research Associate, Angel Broking Ltd
Alkem Laboratories limited reported total revenue from operations at ₹2192 crores up by 7% YoY from ₹2049 crores in Q4FY20. Domestic business has done well for the company up by 17.1% at ₹1473 Crores while Export business down by 8.2% at ₹690.7 Crores. EBITDA for the quarter at ₹291.1 crores down by 3.9% as compared to ₹303 crores in Q4FY20. Company reported below expected EBITDA margin of 13.3% in Q4FY21 as compared to 14.8% in Q4FY20. Profit before tax for the quarter at ₹258.2 crores up by 9.7% as compared to ₹235.3 crores in Q4FY20 as the company able to save certain costs in this quarter. Profit after tax for the quarter at ₹240 crores in Q4FY21 as compared to 188.8₹ crores up by 27% in Q4FY20.
Alkem Laboratories limited reported a mixed set of numbers, revenue growth was better than the market expectation but the International business declined by 8%. We expect the company to do well in the upcoming quarter. On the EBITDA Margin side we have seen significant drop in margins and below the market expectation. We expect this trend to continue in next quarter also and expect a good growth in domestic business in next quarter. We have a neutral view on Alkem Laboratories limited
Above views are of the author and not of the website kindly read disclaimer
.jpg)
